Login

Tag: Kay Holcombe

Kay Holcombe

Washington Focus

Holcombe: ‘Hill Staffers Are Incredibly and Shockingly Important’

Holcombe: ‘Hill Staffers Are Incredibly and Shockingly Important’

Aug. 19, 2019 – As presidential hopefuls discuss the possible merits of “Medicare for All” and other healthcare reforms, discourse in the nation’s capital has deteriorated to the point where “no one talks to each other,” according to Kay Holcombe, who recently retired as senior vice president for science policy at the Biotechnology Innovation Organization. […]

Read more

Courts/First Amendment

Courts’ Support for “Truthful and Non-misleading” Speech Has Not Yet Resulted in FDA Policy Change

Courts’ Support for “Truthful and Non-misleading” Speech Has Not Yet Resulted in FDA Policy Change

May 31, 2016 – Although the U.S. Supreme Court and other courts consistently are deciding cases in favor of First Amendment protections for commercial speech – including speech about off-label uses – the movement toward a “truthful and non-misleading” standard has not moved the needle on this issue at the FDA, according to Alan Bennett, […]

Read more

Categories

Recent Posts

Tags

ACA ad tax CDER chc CMS coalition for healthcare communication conflict of interest Congress COVID-19 data privacy data privacy legislation DDMAC drug prices in DTC ads drug pricing DTC DTC advertising DTC advertising FDA FDA Commissioner FDA Draft Guidance FDA enforcement FDA social media FTC HHS Jim Potter John Kamp Jon Bigelow kamp Kate Rawson legislation litigation off-label off-label communication OPDP OPDP enforcement PhRMA privacy regulation rx data Scott Gottlieb social media sunshine act Untitled Letter Warning Letter Wayne Pines